Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL1243 is a transdermal patch formulation containing a combination of methyl salicylate and menthol, developed by NAL Pharmaceutical Group for pain management. It is designed as an over-the-counter (OTC) product with a 12-hour release profile. The drug acts through a dual mechanism: methyl salicylate serves as a topical analgesic by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, while menthol acts as a counterirritant by activating the Transient Receptor Potential Melastatin 8 (TRPM8) channel, producing a cooling sensation and providing additional analgesic effects. The product is currently in preclinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl salicylate + menthol (Nal Pharmaceuticals).